- Home
- INSM vs GPN Comparison
INSM vs GPN Comparison
Compare INSM & GPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- GPN
- Stock Information
- Founded
- INSM 1988
- GPN 1967
- Country
- INSM United States
- GPN United States
- Employees
- INSM N/A
- GPN N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- GPN Business Services
- Sector
- INSM Health Care
- GPN Consumer Discretionary
- Exchange
- INSM Nasdaq
- GPN Nasdaq
- Market Cap
- INSM 26.0B
- GPN 20.8B
- IPO Year
- INSM 2000
- GPN 2001
- Fundamental
- Price
- INSM $145.86
- GPN $86.07
- Analyst Decision
- INSM Strong Buy
- GPN Buy
- Analyst Count
- INSM 18
- GPN 29
- Target Price
- INSM $146.81
- GPN $114.92
- AVG Volume (30 Days)
- INSM 2.0M
- GPN 2.1M
- Earning Date
- INSM 10-30-2025
- GPN 10-29-2025
- Dividend Yield
- INSM N/A
- GPN 1.16%
- EPS Growth
- INSM N/A
- GPN 4.93
- EPS
- INSM N/A
- GPN 5.73
- Revenue
- INSM $398,105,000.00
- GPN $10,066,209,000.00
- Revenue This Year
- INSM $31.95
- GPN N/A
- Revenue Next Year
- INSM $125.46
- GPN $5.76
- P/E Ratio
- INSM N/A
- GPN $15.03
- Revenue Growth
- INSM 21.15
- GPN 15.51
- 52 Week Low
- INSM $60.40
- GPN $65.93
- 52 Week High
- INSM $149.08
- GPN $120.00
- Technical
- Relative Strength Index (RSI)
- INSM 72.40
- GPN 51.51
- Support Level
- INSM $138.73
- GPN $82.53
- Resistance Level
- INSM $148.22
- GPN $86.92
- Average True Range (ATR)
- INSM 3.85
- GPN 1.85
- MACD
- INSM -0.97
- GPN -0.43
- Stochastic Oscillator
- INSM 78.08
- GPN 52.91
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.